PROSTATE CANCER METASTATIC

This study is for men with hormone-sensitive prostate cancer that has spread to a few places (up to 3 spots) in the bones or lymph nodes. It tests whether adding highly targeted radiation to those spots, on top of standard treatment, can delay the cancer from getting worse. About…

This study tests a new drug, MK-5684, against two standard treatments (abiraterone acetate or enzalutamide) in people with advanced prostate cancer that has spread and no longer responds to hormone therapy or chemotherapy. About 1,310 participants will be randomly assigned to rec…

This study tests whether giving precise, high-dose radiation to visible cancer spots can help men with metastatic prostate cancer who are already responding to hormone therapy. About 80 participants will be randomly chosen to receive either standard care or additional radiation t…

This study tests whether a 12-week exercise program can reduce the number of cancer cells in the blood of men with advanced prostate cancer. Twenty men on hormone therapy will exercise regularly and have their blood tested before, during, and after the program. The goal is to see…

This large phase 3 trial tests two new treatments for prostate cancer that has spread. One uses targeted radiation (SABR) to kill cancer spots, the other uses a radioactive drug (PSMA-Lutetium) that seeks out prostate cancer cells. About 3,360 people will take part, and all conti…

This study tests whether adding darolutamide to standard hormone therapy (ADT) can help men with metastatic prostate cancer who are too frail for stronger treatments. About 300 participants will receive either the drug combination or a placebo. The goal is to see if the combinati…

This study tests whether a 16-week exercise program designed for Black men with prostate cancer can lower their risk of heart disease. Participants are on hormone therapy (ADT), which can increase heart risks. The program includes aerobic and resistance exercises, and the study w…

This early-stage trial tests a new treatment for people with metastatic colorectal or prostate cancer. The treatment uses immune cells (TILs) taken from the patient's own tumor, grown in a lab, and then given back to the patient multiple times. The main goals are to see if it is …

This study tests a new drug called OM-RCA-01 in people with several types of cancer that have spread and have a specific marker (FGFR1). The drug is an antibody given by IV every two weeks. The goal is to find a safe dose and see if it can slow tumor growth. About 58 adults with …

This study tests the drug Enhertu in 60 men with a specific type of advanced prostate cancer (HER2-positive) that has stopped responding to standard hormone therapy and chemotherapy. The goal is to see if Enhertu can shrink tumors or slow the cancer's growth. Participants must ha…

This study follows 130 men with metastatic prostate cancer who are receiving standard treatment with abiraterone and prednisone. Researchers want to see if a person's race or ethnicity affects how well the treatment works, by tracking PSA levels and genetic differences. The goal …

This study looks at whether a type of PET scan (PSMA PET) can predict how well advanced prostate cancer responds to treatments like hormone therapy or chemotherapy. Researchers will track 1,300 men with advanced prostate cancer to see if scan results can forecast treatment succes…

This study looks at whether a special type of PET/CT scan (called dynamic imaging) can find prostate cancer that has spread to other parts of the body more accurately than standard scans. About 60 men with advanced prostate cancer that no longer responds to hormone therapy will g…

This study is creating and testing a simple, patient-friendly tool to help Black or African American men with metastatic prostate cancer understand genetic testing for their tumors. Researchers will interview participants to see if the tool is clear and helpful, and then measure …

This study aims to describe the characteristics of prostate cancer in Algeria, including patient demographics, symptoms, diagnosis methods, and treatments. Researchers will collect information from 2,000 patients aged 19 and older with confirmed prostate cancer. The goal is to be…

This study looks at whether markers in the blood can tell doctors if a man's advanced prostate cancer will respond to hormone therapy. Researchers will collect blood samples from 120 men with metastatic castration-resistant prostate cancer during their standard treatment. They wi…